NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $26.10, for a total transaction of $2,629,000.80. Following the completion of the sale, the insider now owns 10,908,502 shares of the company's stock, valued at $284,711,902.20. This represents a 0.91 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Nap B.V. Forgrowth also recently made the following trade(s):
- On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.39, for a total transaction of $4,215,019.29.
- On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.08, for a total transaction of $834,486.84.
- On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.02, for a total value of $213,420.60.
NewAmsterdam Pharma Price Performance
NASDAQ NAMS traded up $0.04 on Friday, reaching $25.50. 1,026,266 shares of the stock were exchanged, compared to its average volume of 378,655. NewAmsterdam Pharma has a one year low of $10.50 and a one year high of $27.29. The company's 50-day simple moving average is $21.16 and its two-hundred day simple moving average is $18.90.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on NAMS shares. Piper Sandler reissued an "overweight" rating and issued a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Royal Bank of Canada reiterated an "outperform" rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Needham & Company LLC reissued a "buy" rating and issued a $36.00 price objective on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Finally, Scotiabank upped their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a "sector outperform" rating in a report on Wednesday, December 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, NewAmsterdam Pharma has a consensus rating of "Buy" and a consensus target price of $36.20.
View Our Latest Report on NewAmsterdam Pharma
Hedge Funds Weigh In On NewAmsterdam Pharma
Several large investors have recently made changes to their positions in the business. Banque Cantonale Vaudoise purchased a new stake in shares of NewAmsterdam Pharma during the second quarter worth about $38,000. Quarry LP grew its holdings in NewAmsterdam Pharma by 2,469.2% during the 3rd quarter. Quarry LP now owns 6,500 shares of the company's stock valued at $108,000 after buying an additional 6,247 shares in the last quarter. Barclays PLC raised its position in shares of NewAmsterdam Pharma by 1,813.4% during the third quarter. Barclays PLC now owns 7,596 shares of the company's stock valued at $126,000 after buying an additional 7,199 shares during the last quarter. Bellevue Group AG bought a new stake in shares of NewAmsterdam Pharma during the third quarter valued at approximately $128,000. Finally, XTX Topco Ltd purchased a new position in shares of NewAmsterdam Pharma in the third quarter worth $187,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
